State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Infectious Diseases

• Publication date

  2012-09-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/cis818PMID 22990848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective Analysis of Human Cytomegalovirus DNAemia and Specific CD8+ T Cell Responses in Lung Transplant Recipients

  2012influential reference
• Human Cytomegalovirus-Specific T-Cell Immune Reconstitution in Preemptively Treated Heart Transplant Recipients Identifies Subjects at Critical Risk for Infection

  2012influential reference
• Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia

  2012cited by this paper
• Dynamics of cell‐mediated immune responses to cytomegalovirus in pediatric transplantation recipients

  2012cited by this paper
• Virologic and Immunologic Monitoring of Cytomegalovirus to Guide Preemptive Therapy in Solid‐Organ Transplantation

  2011cited by this paper
• Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.

  2011cited by this paper
• Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients

  2011cited by this paper
• Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients.

  2011influential reference
• T cell exhaustion

  2011cited by this paper
• Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections.

  2011cited by this paper
• Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

  2010cited by this paper
• Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.

  2010cited by this paper
• Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation

  2010cited by this paper
• Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.

  2010cited by this paper
• The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients

  2010cited by this paper
• Narrowing of T‐cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients

  2010cited by this paper
• A prospective longitudinal analysis of cytomegalovirus (CMV)‐specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection

  2010cited by this paper
• International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.

  2010cited by this paper
• Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.

  2010cited by this paper
• Experience With Immune Monitoring in Lung Transplant Recipients: Correlation of Low Immune Function With Infection

  2009cited by this paper
• CMV‐specific T‐cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study

  2009cited by this paper
• Cytomegalovirus in Solid Organ Transplant Recipients

  2009cited by this paper
• Cell‐Mediated Immunity to Predict Cytomegalovirus Disease in High‐Risk Solid Organ Transplant Recipients

  2009influential reference
• Long‐Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients

  2009cited by this paper
• Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation.

  2008cited by this paper
• Linking CMV Serostatus to Episodes of CMV Reactivation Following Lung Transplantation by Measuring CMV‐Specific CD8+ T‐Cell Immunity

  2008influential reference
• Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

  2008cited by this paper
• The Number of Activating KIR Genes Inversely Correlates with the Rate of CMV Infection/Reactivation in Kidney Transplant Recipients

  2008cited by this paper
• PD‐1 Expression and IL‐2 Loss of Cytomegalovirus‐ Specific T Cells Correlates with Viremia and Reversible Functional Anergy

  2008cited by this paper
• Ex vivo monitoring of human cytomegalovirus‐specific CD8+ T‐cell responses using QuantiFERON®‐CMV

  2007cited by this paper
• Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.

  2007influential reference
• Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation.

  2007cited by this paper
• Monitoring of Human Cytomegalovirus‐Specific CD4+ and CD8+ T‐Cell Immunity in Patients Receiving Solid Organ Transplantation

  2006cited by this paper
• Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

  2005cited by this paper
• Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients

  2005cited by this paper
• Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells

  2005cited by this paper
• T cells and viral persistence: lessons from diverse infections

  2005cited by this paper
• Differences in CMV‐Specific T‐Cell Levels and Long‐Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation

  2005cited by this paper
• Cellular Immune Responses to Cytomegalovirus in Renal Transplant Recipients

  2005cited by this paper
• Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2004cited by this paper
• Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.

  2002cited by this paper
• Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection.

  2002cited by this paper
• LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1

  2001cited by this paper
• Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

  1994cited by this paper
• Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

  1982cited by this paper

• Expert Consensus on Cytomegalovirus Management in Recipients of CAR-T Cell and Bispecific Antibody Therapies.

  2026cites this paper
• Effector-Memory γδ T Lymphocytes Predict CMV Disease After the Withdrawal of Prophylaxis in Kidney Transplant Recipients

  2025cites this paper
• Tackling CMV in Transplant Recipients: Past, Present, and Future

  2025cites this paper
• Cytomegalovirus Management in Solid Organ Transplant Recipients

  2025cites this paper
• Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3, noninferiority trial

  2025cites this paper
• QuantiFERON monitor predicts early cytomegalovirus infection and viral burden in allogeneic hematopoietic stem cell transplantation

  2024cites this paper
• Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation

  2024cites this paper
• Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity

  2024cites this paper
• Gaining consensus around patient risk groups and prognostic profiles to guide CMV management among patients with solid organ transplant: Insights from a Delphi panel with SOT experts

  2023cites this paper
• Comparison of intracellular cytokine staining versus an ELISA‐based assay to assess CMV‐specific cell‐mediated immunity in high‐risk kidney transplant recipients

  2023cites this paper
• Meet in the middle: Could cell mediated‐immunity assays be the answer for ideal Cytomegalovirus prophylaxis after lung transplantation? Observational study from a single center with intermittent antiviral prophylaxis

  2023cites this paper
• Advances and Challenges in Cytomegalovirus Detection Methods for Liver Transplant Donors

  2023cites this paper
• Clinical utility of a cytomegalovirus‐specific T cell assay in assessing the risk of post‐prophylaxis cytomegalovirus infection and post‐treatment relapse

  2023cites this paper
• Post-transplant dynamics and clinical significance of CMV-specific neutralizing antibodies in kidney transplant recipients treated with T-cell-depleting agents.

  2023cites this paper
• Contemporary Biomarkers for Renal Transplantation: A Narrative Overview

  2023cites this paper
• Prospects of Cytomegalovirus-Specific T-Cell Receptors in Clinical Diagnosis and Therapy

  2023cites this paper
• The influence of HLA A, B, C, DR alleles and HLA haplotypes on cytomegalovirus‐specific cell mediated immunity in seropositive Korean kidney transplant candidates

  2023cites this paper
• Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation

  2022influential citation
• Fifteen-Year Surveillance of LTR Receiving Pre-Emptive Therapy for CMV Infection: Prevention of CMV Disease and Incidence of CLAD

  2022cites this paper
• Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation

  2022cites this paper
• A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection

  2021cites this paper
• Prevention of infections in the solid organ transplantation recipient

  2021cites this paper
• Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation.

  2021cites this paper
• Blood transfusion and the risk for infections in kidney transplant patients

  2021cites this paper
• American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation.

  2021cites this paper
• Development of CMV‐specific cytotoxic T cells (CMV‐Tc) in pediatric renal transplant recipients with CMV viremia

  2021cites this paper
• Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients

  2021influential citation
• Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.

  2021cites this paper
• Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients

  2021cites this paper
• Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

  2021cites this paper
• Post-transplant absolute lymphocyte count predicts early cytomegalovirus infection after heart transplantation

  2021cites this paper
• Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.

  2020cites this paper
• Flow cytometric measurement of STAT5 phosphorylation in cytomegalovirus‐stimulated T cells

  2020cites this paper
• Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients

  2020cites this paper
• Pretransplant CMV-specific T-cell immunity but not dose of antithymocyte globulin is associated with recovery of specific immunity after kidney transplantation.

  2020cites this paper
• Cytomegalovirus Infection in Postrenal Transplant Recipients: 18 Years' Experience From a Tertiary Referral Center.

  2020cites this paper
• Immune Monitoring Using QuantiFERON®-CMV Assay in Congenital Cytomegalovirus Infection: Correlation With Clinical Presentation and CMV DNA load.

  2020cites this paper
• Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact

  2020cites this paper
• Prevention and therapy of viral infections in patients with solid organ transplantation.

  2020cites this paper
• Predictive tools to determine risk of infection in kidney transplant recipients

  2020cites this paper
• Monitoring of CMV‐specific cell‐mediated immunity with a commercial ELISA‐based interferon‐γ release assay in kidney transplant recipients treated with antithymocyte globulin

  2020cites this paper
• Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.

  2019cites this paper
• Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients

  2019cites this paper
• Long-Term Impact of Cytomegalovirus Serologic Status on Lung Transplantation in the United States.

  2019cites this paper
• A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients

  2019cites this paper
• Efficacité antivirale et tolérance d’un régime d’immunosuppression à base d’everolimus et tacrolimus faible dose en transplantation rénale

  2019influential citation
• IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post‐prophylaxis and late period

  2019cites this paper
• Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.

  2019cites this paper
• Risk Assessment of Infections in SOT Recipients

  2019cites this paper
• Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial

  2019cites this paper
• Impacts of Interleukin-18 Polymorphisms on the Incidence of Delayed-Onset Cytomegalovirus Infection in a Cohort of Kidney Transplant Recipients

  2019cites this paper
• Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea

  2019cites this paper
• CMV Prevention and Treatment in Transplantation: What’s New in 2019

  2019cites this paper
• Cytomegalovirus Seroprevalence and Titres in Solid Organ Transplant Recipients and Non-transplant Individuals in Seoul, South Korea

  2019influential citation
• Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.

  2018cites this paper
• Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

  2018cites this paper
• Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients.

  2018cites this paper
• Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.

  2018cites this paper
• New Developments in the Management of Cytomegalovirus Infection After Transplantation

  2018cites this paper
• Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation

  2018cites this paper
• HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition

  2018cites this paper
• Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection

  2018cites this paper
• Clinical validation of a novel enzyme‐linked immunosorbent spot assay‐based in vitro diagnostic assay to monitor cytomegalovirus‐specific cell‐mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study

  2018cites this paper
• Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant

  2018cites this paper
• New therapies for human cytomegalovirus infections.

  2018cites this paper
• CMV specific T cell immunity predicts early viremia after liver transplantation.

  2018cites this paper
• The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients

  2018cites this paper
• T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.

  2018cites this paper
• Detection of glycoproteins B and H genotypes to predict the development of Cytomegalovirus disease in solid organ transplant recipients.

  2018cites this paper
• Late cytomegalovirus (CMV) infections after kidney transplantation under the preemptive strategy: Risk factors and clinical aspects

  2018cites this paper
• Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation

  2017cites this paper
• Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients.

  2017cites this paper
• Viral Infections in Organ Transplant Recipients

  2017cites this paper
• An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation

  2017cites this paper
• Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study

  2017cites this paper
• Viral infections in solid organ transplant recipients: novel updates and a review of the classics

  2017cites this paper
• CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.

  2017cites this paper
• Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies

  2017influential citation
• Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia

  2017cites this paper
• An Interventional Study Using Cell‐Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation

  2017influential citation
• Infection du donneur par le CMV et transplantation rénale : impact sur la réponse immunitaire spécifique et sur la survie des greffons

  2017cites this paper
• Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation

  2017cites this paper
• Expanding role of cytomegalovirus as a human pathogen

  2016cites this paper
• Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention

  2016cites this paper
• Infections in Kidney Transplant Recipients

  2016cites this paper
• Current Perspectives on Cytomegalovirus in Heart Transplantation

  2016cites this paper
• Epstein-Barr Virus and Cytomegalovirus

  2016cites this paper
• Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

  2016cites this paper
• Human MicroRNA Responses Predict Cytomegalovirus Replication Following Solid Organ Transplantation

  2016cites this paper
• Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.

  2016cites this paper
• Monitoring of intracellular adenosine triphosphate in CD4+ T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients

  2016cites this paper
• Cytomegalovirus Infection in Ireland: Seroprevalence, HLA Class I Alleles, and Implications.

  2016cites this paper
• Post‐transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients

  2016cites this paper
• Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants.

  2016cites this paper
• Complexity of Host Micro‐RNA Response to Cytomegalovirus Reactivation After Organ Transplantation

  2016cites this paper
• Cytomegalovirus Infection in Ireland

  2016cites this paper
• Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy

  2016cites this paper
• Cytomegalic hepatitis in a patient receiving omalizumab

  2016influential citation
• Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy

  2016cites this paper
• Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation.

  2016cites this paper